Palatin Technologies

302 articles with Palatin Technologies

• Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 Results; Teleconference and Webcast to be held on September 28, 2020

  9/24/2020

   Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets.

• Palatin Technologies To Present At The H.C. Wainwright & Co. 22nd Annual Global Investment Conference

  9/10/2020

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced today that it will be presenting at the H.C. Wainwright & Co., 22nd Annual Global Investment Conference on Monday, September 14, 2020

• Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference

  8/13/2020

   Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity's 40 th Annual Growth Conference in a Fireside C

• Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

  8/5/2020

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced completion of enrollment of its P

• Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®

  7/27/2020

  Palatin Technologies, Inc. announced that it has mutually terminated the January 2017 license agreement which granted AMAG Pharmaceuticals exclusive North American rights to market Vyleesi®, the first and only on demand treatment for pre-menopausal women suffering from acquired, generalized, hypoactive sexual desire disorder, a condition affecting one in ten premenopausal women.

• Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

  7/8/2020

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced reinitiation of enrollment of its P

• Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders

  6/29/2020

  - Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock - Proposals 1, 2, 3 and 5 were approved at the Annual Meeting - Scheduled to Reconvene July 23, 2020, 9:00 am Eastern Daylight Time

• Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications

  6/23/2020

  - Engages with Scientific, Governmental and Regulatory Agencies - Targeting Q4 2020 Initiation of an Adaptive Phase 2 Trial   [23-June-2020]   CRANBURY, N.J. , June 23, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanoco

• Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

  5/12/2020

  - Dry Eye Disease Phase 2 Study Remains on Track - Data Anticipated in 4Q20 - $89 Million in Cash at March 31, 2020 - Teleconference and Webcast to be held on May 12, 2020

• Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on May 12, 2020

  5/7/2020

  Palatin Technologies, Inc. will announce its third quarter fiscal year 2020 operating results on Tuesday, May 12, 2020 before the open of the U.S. financial markets.

• Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations

  4/30/2020

  Dry Eye Disease Phase 2 Study Remains on Track - Data Anticipated in 4Q20

• Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643

  2/19/2020

  CRANBURY, N.J. , Feb. 19, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled

• Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

  2/11/2020

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2019.

• Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020

  2/6/2020

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets.

• Palatin Provides Corporate Update and 2020 Calendar Outlook

  1/21/2020

  Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, provided a corporate update and outlook for calendar year 2020.

• Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

  11/13/2019

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2019.

• Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019

  11/7/2019

  Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2020 operating results on Wednesday, November 13, 2019 before the open of the U.S. financial markets.

• Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

  10/17/2019

  Dr. Dodd was invited by symposium organizers to speak about the challenges of peptide drug development.

• Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

  10/16/2019

  Palatin Technologies, Inc. announced that data from two pivotal, double-blind placebo-controlled Phase 3 trials and the Exit Survey/Interview data on Vyleesi™ for hypoactive sexual desire disorder will be presented at the 13th European Society of Gynecology Conference in Vienna, Austria.

• Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

  9/12/2019

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2019.